On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Employs Proprietary Biosynthetic Processes to Develop Ultra-Pure CBD

Company: Willow Biosciences Inc. (WLLW)
Category: Stock Spotlights

Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. An article further discussing the company reads, “The video (http://cnw.fm/7MJm1) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco that will build on Willow’s experience in developing manufacturing processes for active pharmaceutical ingredients (‘APIs’) that treat conditions such as cancer, pain and central nervous system disorders, as well as Noramco’s experience in producing high-quality, synthetic cannabinoid APIs for the pharmaceutical and health care industry. . . . Under the agreement, Willow will focus on developing ultra-pure CBD with its pioneering biosynthetic technology, bypassing the costs and waste associated with plant cultivation for a single cannabinoid by optimizing yeast cultivation processes, while Noramco will be responsible for the scale-up, regulatory applications, marketing and distribution of the companies’ products. Their work has the potential to open new and larger markets for CBD and related compounds, as well as providing low-cost solutions to pharmaceutical partners.”

To view the full article, visit http://cnw.fm/CvP5V

About Willow Biosciences Inc.

Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high-value, plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management and CNS disorders. In the cannabinoid field, Willow owns proprietary, yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC) and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at www.WillowBio.com.

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Official NewsWire Relationships

Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722